company background image
A042520 logo

HansBiomed KOSDAQ:A042520 Stock Report

Last Price

₩8.50k

Market Cap

₩110.4b

7D

-2.7%

1Y

-27.5%

Updated

07 Feb, 2025

Data

Company Financials

HansBiomed Corporation

KOSDAQ:A042520 Stock Report

Market Cap: ₩110.4b

A042520 Stock Overview

Engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. More details

A042520 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

HansBiomed Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for HansBiomed
Historical stock prices
Current Share Price₩8,500.00
52 Week High₩16,600.00
52 Week Low₩6,500.00
Beta0.68
1 Month Change-4.39%
3 Month Change3.91%
1 Year Change-27.54%
3 Year Change-31.45%
5 Year Change-66.93%
Change since IPO34.71%

Recent News & Updates

HansBiomed Corporation's (KOSDAQ:042520) Low P/S No Reason For Excitement

Dec 09
HansBiomed Corporation's (KOSDAQ:042520) Low P/S No Reason For Excitement

Is HansBiomed (KOSDAQ:042520) A Risky Investment?

Oct 29
Is HansBiomed (KOSDAQ:042520) A Risky Investment?

Recent updates

HansBiomed Corporation's (KOSDAQ:042520) Low P/S No Reason For Excitement

Dec 09
HansBiomed Corporation's (KOSDAQ:042520) Low P/S No Reason For Excitement

Is HansBiomed (KOSDAQ:042520) A Risky Investment?

Oct 29
Is HansBiomed (KOSDAQ:042520) A Risky Investment?

Is HansBiomed (KOSDAQ:042520) A Risky Investment?

Feb 29
Is HansBiomed (KOSDAQ:042520) A Risky Investment?

HansBiomed Corporation (KOSDAQ:042520) Shares Fly 25% But Investors Aren't Buying For Growth

Feb 29
HansBiomed Corporation (KOSDAQ:042520) Shares Fly 25% But Investors Aren't Buying For Growth

Are Dividend Investors Making A Mistake With HansBiomed Corporation (KOSDAQ:042520)?

Apr 10
Are Dividend Investors Making A Mistake With HansBiomed Corporation (KOSDAQ:042520)?

Does HansBiomed (KOSDAQ:042520) Have A Healthy Balance Sheet?

Mar 06
Does HansBiomed (KOSDAQ:042520) Have A Healthy Balance Sheet?

HansBiomed's(KOSDAQ:042520) Share Price Is Down 63% Over The Past Three Years.

Jan 30
HansBiomed's(KOSDAQ:042520) Share Price Is Down 63% Over The Past Three Years.

Are HansBiomed's (KOSDAQ:042520) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Dec 08
Are HansBiomed's (KOSDAQ:042520) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Declining Stock and Decent Financials: Is The Market Wrong About HansBiomed Corporation (KOSDAQ:042520)?

Nov 20
Declining Stock and Decent Financials: Is The Market Wrong About HansBiomed Corporation (KOSDAQ:042520)?

Shareholder Returns

A042520KR BiotechsKR Market
7D-2.7%2.2%0.5%
1Y-27.5%30.3%-5.3%

Return vs Industry: A042520 underperformed the KR Biotechs industry which returned 30.7% over the past year.

Return vs Market: A042520 underperformed the KR Market which returned -4.9% over the past year.

Price Volatility

Is A042520's price volatile compared to industry and market?
A042520 volatility
A042520 Average Weekly Movement7.4%
Biotechs Industry Average Movement8.8%
Market Average Movement6.9%
10% most volatile stocks in KR Market13.0%
10% least volatile stocks in KR Market3.5%

Stable Share Price: A042520 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A042520's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1990127Guen Young Kimwww.hansbiomed.com

HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product that transplanted in a patient whose skin has been lost due to breast cancer; and SureDerm, an acellular dermal matrix. It also offers BELLAGEL, a breast prosthesis, internal, and gel-filled solution; MINT Lift, a PDO thread; EZ-Tcon solution; Lion HT/HN, a hair transplanter body/needle; and Scar Clinic, a scar management solution.

HansBiomed Corporation Fundamentals Summary

How do HansBiomed's earnings and revenue compare to its market cap?
A042520 fundamental statistics
Market cap₩110.39b
Earnings (TTM)-₩7.22b
Revenue (TTM)₩81.14b

1.4x

P/S Ratio

-15.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A042520 income statement (TTM)
Revenue₩81.14b
Cost of Revenue₩29.39b
Gross Profit₩51.75b
Other Expenses₩58.97b
Earnings-₩7.22b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-556.17
Gross Margin63.78%
Net Profit Margin-8.90%
Debt/Equity Ratio51.1%

How did A042520 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 05:01
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HansBiomed Corporation is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jong Kyung ChoiDAOL Investment & Securities Co., Ltd.
Sang-Hun LeeiM Securities
Seung Kyu JungKiwoom Securities Co., Ltd.